Radisens’ addressable market is in excess of $3 billion, growing at 12% annually. Our disruptive medical diagnostics technology offers one single platform with a suite of consumables to address multiple diagnostic applications including the deteciton of infectious diseases, early cancers, thyroid inflammation and blood counting. Our USP’s include integrated sample preparation, a sample-to-answer process, removing the need for a trained operator, auto-calibration, handheld operation and significant reliability advances. We have significant market traction, and are already in advanced discussions with Tier I diagnostic companies to commercialise our first platform offering.

You will find a further outline in our market and technology sections. Due to the commercially sensitive nature of our product and business development, this outline is necessarily broad. Additional information about our technology, sales & marketing strategy and financial projections is available offline through discussion with our experienced team. If you’re interested in seeing a complete Investor Prospectus, you’re welcome to contact us.

Investors

The company is currently funded by the promoters, private business angels, Cork City Enterprise Board, Sophia Business Angels and Enterprise Ireland. Radisens is actively seeking follow-on investment for private angels and institutional seed investors. If you would like to talk to us about investment in Radisens, or are interested in viewing an Investor Prospectus, we would be delighted to hear from you.